AstraZeneca has set an ambitious target to increase its revenue to 80 billion USD by 2030 and plans to significantly boost its investments in technologies and platforms.

Ahead of its investor day on Tuesday, the British-Swedish pharmaceutical company announced that it will develop 20 new drugs over the next six years and expects significant growth in all its therapeutic areas.

To achieve this sales target, the company aims for a core operating profit margin in the mid-30 percent range by 2026. After 2026, the core operating profit margin will be influenced by the development of the portfolio, with at least the mid-30 percent range being targeted, according to AstraZeneca.

The company expects sustainable growth even after 2030.

Last year, AstraZeneca achieved sales of 45.81 billion USD and a core earnings per share—the company's preferred metric—of 7.26 USD.

Last month, the company reported an increased performance in its key metrics and reaffirmed its annual forecast.

The revenue for the quarter increased by 19% to 12.68 billion USD, while the core earnings per share rose by 13% to 2.06 USD.

AstraZeneca Expects Revenue and Core Profit Increase in the Low Double-Digit to Low Teen Percentage Range for the Year.